Phase 3 Clinical Trials With Primary Completion Dates in June 2023

This is a list of Phase 3 trials with primary completion dates in June 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ALVO Alvotech 2023-06-01 Phase 3 NCT05155293 Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)
ANVS Annovis Bio, Inc. 2023-06-01 Phase 3 NCT05357989 A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
AXSM Axsome Therapeutics, Inc. 2023-06-01 Phase 3 NCT05059223 A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy
AXSM Axsome Therapeutics, Inc. 2023-06-01 Phase 3 NCT04947553 Open-Label Safety Study of AXS-05 in Subjects With Alzheimer's Disease Agitation
CING Cingulate Inc. 2023-06-01 Phase 3 NCT05631626 Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
CLVSQ Clovis Oncology, Inc. 2023-06-01 Phase 3 NCT04227522 Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients
CORT Corcept Therapeutics Incorporated 2023-06-01 Phase 3 NCT04308590 Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
DBVT DBV Technologies S.A. 2023-06-01 Phase 3 NCT03859700 Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children
EBS Emergent BioSolutions Inc. 2023-06-01 Phase 3 NCT05349617 Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
MMSI Merit Medical Systems, Inc. 2023-06-01 Phase 3 NCT03960008 Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
ORGO Organogenesis Holdings Inc. 2023-06-01 Phase 3 NCT04636229 Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
SAGE Sage Therapeutics, Inc. 2023-06-01 Phase 3 NCT03864614 A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
SLNO Soleno Therapeutics, Inc. 2023-06-01 Phase 3 NCT03714373 Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period
TNXP Tonix Pharmaceuticals Holding Corp. 2023-06-01 Phase 3 NCT05273749 A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia
ZLDPF Zealand Pharma A/S 2023-06-01 Phase 3 NCT05378672 A Research Study to Investigate the Safety and Effect of Dasiglucagon as a Hypoglycemia Rescue Therapy and How it Works in the Body of Children Under 6 Years of Age With Type 1 Diabetes